HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications and The University of Texas MD Anderson Cancer Center have entered into a 2-year Sponsored Research Agreement to support development of multiple next-generation sequencing (NGS)-based gene expression assays for lung cancer subtyping, fusion status and immune profiling. The project will use the HTG EdgeSeq system and products for molecular profiling of multiple well-characterized samples from cohorts including the Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) lung cancer trial. HTG EdgeSeq technology enables researchers to measure quantitative expression of both message (mRNA) and microRNA (miRNA) from very small, challenging sample types such as formalin-fixed, paraffin-embedded (FFPE) tissues and plasma from blood. Automated on the HTG EdgeSeq system, HTG EdgeSeq technology couples HTG’s proprietary nuclease protection chemistry with NGS.
HTG expects the project will provide critical information for selection of novel therapies and better predict outcomes in lung cancer patients than currently accepted genomic analysis alone.
“We are thrilled to partner with MD Anderson in this Sponsored Research Agreement to investigate new assays to better diagnose and treat patients diagnosed with lung cancer,” stated TJ Johnson, HTG Molecular Chief Executive Officer.
Headquartered in Tucson, Arizona, HTG Molecular Diagnostics’ mission is to provide simple, cost effective solutions for accurate RNA testing. In 2013 the company commercialized its HTG Edge instrument platform and a portfolio of RNA assays that leverage HTG’s proprietary nuclease protection chemistry. HTG Edge system capabilities have been expanded to fully automate sample and targeted library preparation for next-generation sequencing.Additional information is available at www.htgmolecular.com.
Note: Click here for the orginal press release and Forward Looking Statements